News SoftOx Solutions

Stocks

SOFTX

NO0010811961

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 15:45:00 10/06/2026 BST			5-day change	1st Jan Change
0.1168 ^NOK	-4.42%		+2.46%	+33.03%

06-08	SoftOx Solutions AS announced that it expects to receive NOK 6.029468 million in funding from Long State Investments Limited	CI
06-05	SoftOx Solutions AS Enrolls First Participant In SIS-02 Phase 1 Clinical Study	CI

All News

Mentions Relevance

06-09	SoftOx Solutions AS: Notice of General Assembly	AQ
06-09	SoftOx Solutions AS: SoftOx Solutions AS exercises on the financing facility with Long State Investments Limited	AQ
06-08	SoftOx Solutions AS announced that it expects to receive NOK 6.029468 million in funding from Long State Investments Limited	CI
06-08	SoftOx Solutions AS: SIS-03 DOSE-ESCALATION PHASE COMPLETED AND INITIATION OF PROOF-OF-CONCEPT PHASE	AQ
06-05	SoftOx Solutions AS Enrolls First Participant In SIS-02 Phase 1 Clinical Study	CI
06-05	SoftOx Solutions Enrolls First Patient in Clinical Trial of Inhalation Therapy	MT
06-05	SoftOx Solutions AS: FIRST PARTICIPANT ENROLLED IN BIODEFENCE-FOCUSED SIS-02 PHASE 1 CLINICAL STUDY	AQ
05-27	SoftOx Solutions AS: Annual Report 2025	AQ
04-21	SoftOx Solutions AS: New Share Capital	AQ
04-13	Softox Solutions Issues Shares to Long State Investments Under Committed Financing Facility Deal	MT
04-13	SoftOx Solutions AS: SoftOx Solutions AS exercises on the financing facility with Long State Investments Limited	AQ
04-12	SoftOx Solutions AS announced that it expects to receive NOK 7.2 million in funding from Long State Investments Limited	CI
03-25	SoftOx Solutions AS Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
03-25	SoftOx Solutions AS: Fourth Quarter Report 2025	AQ
03-24	SoftOx Solutions AS: New Share Capital	AQ
03-11	SoftOx Solutions AS: SoftOx Solutions AS exercises on the financing facility with Long State Investments Limited	AQ
03-03	Softox Solutions as Announces First Subject Dosed in Combined Phase 2A Dose-Escalation and Proof-Of-Concept Trial	CI
03-03	SoftOx Solutions AS: First Subject Dosed in Combined Phase 2a Dose-Escalation and Proof-of-Concept Trial (SIS-03)	AQ
02-25	Health Products Regulatory Authority Approves SIS-02 Phase 1 Trial, Strengthening Dual-Use and Preparedness Strategy	CI
02-25	SoftOx Defense Solutions AS: HPRA Approves SIS-02 Phase 1 Trial, Strengthening Dual-Use and Preparedness Strategy	AQ
02-04	SoftOx Solutions AS: New Share Capital	AQ
01-23	SoftOx Solutions AS: SoftOx Solutions AS exercises on the financing facility with Long State Investments Limited	AQ
12-29	Danish Medicines Agency Approves Phase 2A Trial for Softox Inhalation Solution	CI
12-29	SoftOx Solutions Lands Approval for Inhalation Therapy's Mid-stage Study in Denmark	MT
12-29	SoftOx Solutions AS: Danish Medicines Agency Approves Phase 2a Trial for SoftOx Inhalation Solution	AQ